Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020223608 - INHIBITION OF IL-1 AND IL-6 INFLAMMATION

Publication Number WO/2020/223608
Publication Date 05.11.2020
International Application No. PCT/US2020/030974
International Filing Date 01.05.2020
IPC
A61P 37/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
06Immunosuppressants, e.g. drugs for graft rejection
A61K 31/105 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
095Sulfur, selenium or tellurium compounds, e.g. thiols
105Persulfides
A61K 31/455 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
455Nicotinic acid, i.e. niacin; Derivatives thereof, e.g. esters, amides
A61K 31/505 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
A61P 29/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
A61P 37/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
Applicants
  • THIOLAB, LLC,
Inventors
  • GRASSETTI, Davide, R.
  • MORO, Camillo
  • GRASSETTI, Richard, A.
Agents
  • BAKER, Gary
Priority Data
62/842,08102.05.2019US
63/010,55315.04.2020US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) INHIBITION OF IL-1 AND IL-6 INFLAMMATION
(FR) INHIBITION DE L'INFLAMMATION D'IL-1 ET D'IL-6
Abstract
(EN)
This invention provides methods of treatment for a variety of inflammation pathologies using thione-forming disulfides (TFDs). The treatments are particularly effective in the context of inflammations primarily due to excessive activity of innate immune system components, macrophage activity and inflammation arising from excessive production of IL-1. TFD inhibition of both IL-1 and IL-6 can reduce the detrimental effects of the cytokine storms known to increase morbidity and mortality caused by certain infections, such as COVID-19 viral pneumonia.
(FR)
La présente invention concerne des procédés de traitement pour une variété de pathologies inflammatoires à l'aide de disulfures formant des thiones (TFD). Les traitements sont particulièrement efficaces dans le contexte d'inflammations principalement dues à une activité excessive des composants du système immunitaire inné, une activité des macrophages et une inflammation résultant d'une production excessive d'IL-1. L'inhibition par TFD à la fois d'IL-1 et d'IL-6 peut réduire les effets néfastes des tempêtes de cytokine connus pour augmenter la morbidité et la mortalité provoquées par certaines infections, telles que la pneumonie virale COVID-19.
Latest bibliographic data on file with the International Bureau